Boehringer Ingelheim's polo-like kinase (Plk) inhibitor volasertib improved survival by nearly three months for elderly patients with acute myeloid leukemia (AML) in the Phase II clinical trial that served as justification to start the German company's an ongoing Phase III trial.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?